Flexion Therapeutics, Inc. (NASDAQ:FLXN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

A number of other equities analysts have also recently commented on the stock. Wells Fargo & Company set a $39.00 price target on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research note on Monday. Royal Bank Of Canada set a $44.00 price target on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research note on Sunday. ValuEngine cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Laidlaw reiterated a “buy” rating and set a $38.00 price objective (up previously from $35.00) on shares of Flexion Therapeutics in a report on Tuesday, October 10th. Finally, Janney Montgomery Scott lifted their price objective on shares of Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $88.50.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11).

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Upgrades Flexion Therapeutics, Inc. (FLXN) to Hold” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/01/zacks-investment-research-upgrades-flexion-therapeutics-inc-flxn-to-hold.html.

In other Flexion Therapeutics news, insider Yamo Deniz purchased 3,000 shares of Flexion Therapeutics stock in a transaction dated Friday, September 1st. The stock was acquired at an average price of $24.15 per share, for a total transaction of $72,450.00. Following the acquisition, the insider now owns 5,000 shares in the company, valued at approximately $120,750. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders bought 5,375 shares of company stock valued at $131,575. Company insiders own 15.98% of the company’s stock.

Several large investors have recently bought and sold shares of FLXN. Fiduciary Trust Co. bought a new stake in shares of Flexion Therapeutics in the 2nd quarter valued at about $101,000. IFP Advisors Inc raised its holdings in shares of Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,000 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new stake in shares of Flexion Therapeutics in the 3rd quarter valued at about $235,000. Finally, Voya Investment Management LLC raised its holdings in shares of Flexion Therapeutics by 25.8% in the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after purchasing an additional 2,651 shares in the last quarter. Institutional investors and hedge funds own 72.31% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.